The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £23.55. The company’s shares closed ...

Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Biotech company 23andMe had a rough 2024, including a $30 million settlement payment after customer data was compromised.

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.